|
Strategic Partnership Signed Between Rönesans and SJ Group to help continue to deliver the DAPEK Industrial Zone
ISTANBUL , March 25, 2026 /PRNewswire/ -- Rönesans Holding has announced a strategic partnership with SJ Group, as part of the development of the Eastern Mediterranean Petrochemical Industrial Zone and Port (DAPEK) project in Ceyhan, Adana.
Spanning 2,750 hectares with two kilometres of coastline, DAPEK is a next‑generation logistics and energy hub of national strategic importance within Türkiye's energy and trade corridor. Initiated with the start of construction in 2025, the project is anchored by a world‑scale polypropylene production facility, supported by integrated infrastructure including bulk liquid and container terminals, a solar power plant, and a green hydrogen production facility.
As the management partner, SJ Group will bring global best practices to DAPEK's development. This includes the preparation of strategic development plans, land-use planning, and integration of new manufacturers into industrial clusters. The collaboration combines Rönesans Holding's large-scale infrastructure know-how with SJ Group's renowned expertise in industrial planning and investor networks, notably their work on Singapore's Jurong Island.
Developed by Rönesans Holding in close coordination with the Ministry of Industry and Technology, infrastructure investments in the Industrial Zone are specifically designed to align with the needs of global investors, with a focus on high-capital, export-oriented investments. Building on consultancy support provided since 2025, this formalised partnership will see SJ Group introduce investor-friendly solutions including, streamlined processes, enhanced operational efficiency, and accelerated project delivery timelines.
PARTNERSHIP ADVANCES SUSTAINABLE GROWTH GOALS
Erman Ilıcak, President Emeritus of Rönesans Holding, said: "We believe that international partnerships are a key driver of sustainable growth. These collaborations, which bring together a global perspective with strong local expertise, present a powerful model for industrial development. An approach that aligns technological innovation with environmental responsibility will help create long-term value for Türkiye and the wider region.
At Rönesans we are also the anchor investor at DAPEK, investing $2 billion to the development of a PDH/PP plant and a liquid bulk terminal. This project is expected to be operational by the end of 2027 and contribute approximately $300 million annually to Türkiye's current account balance. With global experience in industrial master planning, energy infrastructure, and sustainability, SJ Group will contribute to strengthening DAPEK's long-term strategy and supporting our sustainable growth goals."
A MODEL FOR REGIONAL INDUSTRIAL DEVELOPMENT
Tan Wooi Leong, Senior Executive Director, Energy at SJ, said, "Our collaboration with Rönesans marks a significant milestone for SJ as we strengthen our role as a leading global advisor in the development of major industrial and port-based clusters, particularly those focused on energy transition and emerging technologies towards a net zero manufacturing site. Our deep expertise in industrial parks and economic zones will help establish DAPEK as a role model for industrial development in the region, while reinforcing its role in advancing Türkiye's long-term industrial growth and infrastructure ambitions."
About Rönesans Group
Rönesans Holding, the conglomerate's leading investment entity headquartered in Ankara, is the 50th largest international contracting company globally and one of the largest in Europe. With operations spanning 40 countries across Europe, Central Asia, and Africa, including subsidiaries such as Ballast Nedam in the Netherlands and Heitkamp Industrial Solutions GmbH in Germany, Rönesans has been operating as the main contractor and investor successfully for more than 30 years in construction, real estate, concession, energy and industrial investments. Putting resilience and growth through innovation at the core of the company, with a priority on sustainability and social development, Rönesans has developed projects supporting students with scholarships, academic platforms and initiatives; been a signatory of the UN Global Compact since 2015; and a signatory of the UN Women's Empowerment Principles since 2016.
Under the leadership of its President Emeritus, Erman Ilıcak, Rönesans, along with its partners GIC, Meridiam Infrastructure, Sojitz, Samsung C&T, TotalEnergies, and IFC of the World Bank Group (minority shareholder in the group), has invested more than $10 billion into pioneering projects globally.
About SJ Group
SJ is a diverse collective of problem solvers for the built environment, continually reimagining ways to create a smart and sustainable future.
Headquartered in Singapore, the group has a global talent pool of 16,000 in its member companies AETOS, Atelier Ten, B+H, CHIL, KTP, Prostruct, Robert Bird Group, SAA, SMEC and Surbana Jurong, based in more than 120 offices in over 40 countries. They include architects, designers, planners, engineers, facilities managers and other specialists driven by progressive thinking and creative ideas to shape a better future.
Its technical experts deliver sustainable solutions that cover the entire project life cycle from planning and design, through to delivery and management, as well as a full suite of multidisciplinary consultancy services across a diverse range of sectors including transportation, water, aviation, healthcare, hospitality and renewables.
A global urban, infrastructure and managed services consulting firm with over 70 years of track record in successful project delivery, SJ has built more than a million homes in Singapore, created master plans in more than 60 countries and developed over 100 industrial parks globally.
SJ is #23 in Engineering News-Record's Top 225 International Design Firms, #17 in World Architecture 100 2025, and Asia Pacific FM Technology Provider of the Year 2022, awarded by International Facility Management Association.
Strategic Partnership Signed Between Rönesans and SJ Group to help continue to deliver the DAPEK Industrial Zone
ISTANBUL , March 25, 2026 /PRNewswire/ -- Rönesans Holding has announced a strategic partnership with SJ Group, as part of the development of the Eastern Mediterranean Petrochemical Industrial Zone and Port (DAPEK) project in Ceyhan, Adana.
Spanning 2,750 hectares with two kilometres of coastline, DAPEK is a next‑generation logistics and energy hub of national strategic importance within Türkiye's energy and trade corridor. Initiated with the start of construction in 2025, the project is anchored by a world‑scale polypropylene production facility, supported by integrated infrastructure including bulk liquid and container terminals, a solar power plant, and a green hydrogen production facility.
As the management partner, SJ Group will bring global best practices to DAPEK's development. This includes the preparation of strategic development plans, land-use planning, and integration of new manufacturers into industrial clusters. The collaboration combines Rönesans Holding's large-scale infrastructure know-how with SJ Group's renowned expertise in industrial planning and investor networks, notably their work on Singapore's Jurong Island.
Developed by Rönesans Holding in close coordination with the Ministry of Industry and Technology, infrastructure investments in the Industrial Zone are specifically designed to align with the needs of global investors, with a focus on high-capital, export-oriented investments. Building on consultancy support provided since 2025, this formalised partnership will see SJ Group introduce investor-friendly solutions including, streamlined processes, enhanced operational efficiency, and accelerated project delivery timelines.
PARTNERSHIP ADVANCES SUSTAINABLE GROWTH GOALS
Erman Ilıcak, President Emeritus of Rönesans Holding, said: "We believe that international partnerships are a key driver of sustainable growth. These collaborations, which bring together a global perspective with strong local expertise, present a powerful model for industrial development. An approach that aligns technological innovation with environmental responsibility will help create long-term value for Türkiye and the wider region.
At Rönesans we are also the anchor investor at DAPEK, investing $2 billion to the development of a PDH/PP plant and a liquid bulk terminal. This project is expected to be operational by the end of 2027 and contribute approximately $300 million annually to Türkiye's current account balance. With global experience in industrial master planning, energy infrastructure, and sustainability, SJ Group will contribute to strengthening DAPEK's long-term strategy and supporting our sustainable growth goals."
A MODEL FOR REGIONAL INDUSTRIAL DEVELOPMENT
Tan Wooi Leong, Senior Executive Director, Energy at SJ, said, "Our collaboration with Rönesans marks a significant milestone for SJ as we strengthen our role as a leading global advisor in the development of major industrial and port-based clusters, particularly those focused on energy transition and emerging technologies towards a net zero manufacturing site. Our deep expertise in industrial parks and economic zones will help establish DAPEK as a role model for industrial development in the region, while reinforcing its role in advancing Türkiye's long-term industrial growth and infrastructure ambitions."
About Rönesans Group
Rönesans Holding, the conglomerate's leading investment entity headquartered in Ankara, is the 50th largest international contracting company globally and one of the largest in Europe. With operations spanning 40 countries across Europe, Central Asia, and Africa, including subsidiaries such as Ballast Nedam in the Netherlands and Heitkamp Industrial Solutions GmbH in Germany, Rönesans has been operating as the main contractor and investor successfully for more than 30 years in construction, real estate, concession, energy and industrial investments. Putting resilience and growth through innovation at the core of the company, with a priority on sustainability and social development, Rönesans has developed projects supporting students with scholarships, academic platforms and initiatives; been a signatory of the UN Global Compact since 2015; and a signatory of the UN Women's Empowerment Principles since 2016.
Under the leadership of its President Emeritus, Erman Ilıcak, Rönesans, along with its partners GIC, Meridiam Infrastructure, Sojitz, Samsung C&T, TotalEnergies, and IFC of the World Bank Group (minority shareholder in the group), has invested more than $10 billion into pioneering projects globally.
About SJ Group
SJ is a diverse collective of problem solvers for the built environment, continually reimagining ways to create a smart and sustainable future.
Headquartered in Singapore, the group has a global talent pool of 16,000 in its member companies AETOS, Atelier Ten, B+H, CHIL, KTP, Prostruct, Robert Bird Group, SAA, SMEC and Surbana Jurong, based in more than 120 offices in over 40 countries. They include architects, designers, planners, engineers, facilities managers and other specialists driven by progressive thinking and creative ideas to shape a better future.
Its technical experts deliver sustainable solutions that cover the entire project life cycle from planning and design, through to delivery and management, as well as a full suite of multidisciplinary consultancy services across a diverse range of sectors including transportation, water, aviation, healthcare, hospitality and renewables.
A global urban, infrastructure and managed services consulting firm with over 70 years of track record in successful project delivery, SJ has built more than a million homes in Singapore, created master plans in more than 60 countries and developed over 100 industrial parks globally.
SJ is #23 in Engineering News-Record's Top 225 International Design Firms, #17 in World Architecture 100 2025, and Asia Pacific FM Technology Provider of the Year 2022, awarded by International Facility Management Association.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Rönesans Holding Announces New Global Partnership
Rönesans Holding Announces New Global Partnership
|
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People's Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.
The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.
The confirmed objective response rate (ORR) assessed by Independent Review Committee (IRC) was 81.3% (95% CI: 71.8–88.7) in treatment-naïve patients and 87.1% (95% CI: 77.0–93.9) in pre-treated patients.
In treatment-naïve patients, median duration of response (mDOR) and median progression-free survival (mPFS) were not reached. In pre-treated patients, mDOR was 25.7 months, and mPFS was 27.5 months.
Among 40 patients with central nervous system (CNS) metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).
Lunbotinib fumarate was well tolerated, with treatment-related adverse events (TRAEs) being predominantly Grade 1–2. The rate of permanent discontinuation due to TRAEs was 1.2%, and no treatment-related deaths were reported.
The study shows that lunbotinib fumarate demonstrated robust and durable clinical activity in RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.
Professor Qing Zhou, principal investigator from Guangdong Provincial People's Hospital, said: "From the first presentation of Phase I data at ASCO 2023 to today's pivotal Phase II results, we have witnessed the progression of lunbotinib fumarate from early exploration to a confirmatory study. These data show that lunbotinib fumarate delivers robust and durable responses in both treatment-naïve and pre-treated patients with RET fusion-positive NSCLC, with particularly remarkable intracranial efficacy in patients with CNS metastases at baseline. As a next-generation selective RET inhibitor, it will offer an important new treatment option for patients."
| [1] Trade name to be approved by NMPA. |
|
About lunbotinib fumarate (A400/EP0031, 宁泰莱®)
Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.
In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People's Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.
The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.
The confirmed objective response rate (ORR) assessed by Independent Review Committee (IRC) was 81.3% (95% CI: 71.8–88.7) in treatment-naïve patients and 87.1% (95% CI: 77.0–93.9) in pre-treated patients.
In treatment-naïve patients, median duration of response (mDOR) and median progression-free survival (mPFS) were not reached. In pre-treated patients, mDOR was 25.7 months, and mPFS was 27.5 months.
Among 40 patients with central nervous system (CNS) metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).
Lunbotinib fumarate was well tolerated, with treatment-related adverse events (TRAEs) being predominantly Grade 1–2. The rate of permanent discontinuation due to TRAEs was 1.2%, and no treatment-related deaths were reported.
The study shows that lunbotinib fumarate demonstrated robust and durable clinical activity in RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.
Professor Qing Zhou, principal investigator from Guangdong Provincial People's Hospital, said: "From the first presentation of Phase I data at ASCO 2023 to today's pivotal Phase II results, we have witnessed the progression of lunbotinib fumarate from early exploration to a confirmatory study. These data show that lunbotinib fumarate delivers robust and durable responses in both treatment-naïve and pre-treated patients with RET fusion-positive NSCLC, with particularly remarkable intracranial efficacy in patients with CNS metastases at baseline. As a next-generation selective RET inhibitor, it will offer an important new treatment option for patients."
[1] Trade name to be approved by NMPA.
About lunbotinib fumarate (A400/EP0031, 宁泰莱®)
Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.
In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
